The utility of the [TIMP-2]*[IGFBP7] day 0 clinical risk prediction model was confirmed in the validation cohort, with a sensitivity and specificity of 88.8% and 92.6%, respectively; and (3) urine [TIMP-2]*[IGFBP7], TIMP-2 alone, and IGFBP7 alone on day 1 performed poorly for predicting AKI recovery. This evidence concerns the gene TIMP2 and acute kidney injury.